8-K: Acasti Pharma Reports Q3 2024 Financial Results and Provides Business Update

Acasti Pharma announced its third fiscal quarter 2024 results, highlighting progress with its GTX-104 clinical trial and an extended cash runway into the second quarter of 2026.

Summary

• Acasti Pharma reported a net loss of $2.4 million, or $0.21 per share, for the quarter ended December 31, 2023, which is an improvement compared to a net loss of $3.9 million, or $0.52 per share, for the same period in 2022.
• The company's operating expenses were $3.0 million, offset by $0.3 million in interest income, a $0.1 million gain on derivative warrant liabilities, and $0.2 million in income tax recovery.
• Research and development expenses decreased to $1.4 million from $2.5 million year-over-year due to a strategic realignment plan.
• General and administrative expenses remained stable at $1.6 million.
• Acasti's cash, cash equivalents, and short-term investments totaled $25.1 million as of December 31, 2023.
• The company's cash runway is projected to extend into the second calendar quarter of 2026, beyond the anticipated NDA submission for GTX-104 in the first half of 2025.
• The first patient was dosed in the STRIVE-ON trial in October, and patient enrollment is ongoing.
• The addressable market for GTX-104 in the United States is estimated to be around $300 million.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with improved financial results, a strong cash position, and progress in clinical trials. However, the company is still in the clinical stage and faces regulatory and commercialization risks.

Positives

• The company's cash runway has been extended to the second quarter of 2026, providing financial stability.
• The STRIVE-ON trial is progressing as planned, with the first patient dosed and enrollment continuing.
• The net loss has decreased compared to the same quarter last year, indicating improved financial performance.
• Research and development expenses have been reduced due to a strategic realignment, improving cash flow.
• The company has a strong cash position of $25.1 million.
• GTX-104 has been well tolerated in over 150 healthy volunteers with lower pharmacokinetic variability compared to oral nimodipine.

Negatives

• The company reported a net loss of $2.4 million for the quarter.
• The company is still in the clinical stage and not yet generating revenue from product sales.
• The company is reliant on the success of the GTX-104 clinical trial and regulatory approval.

Risks

• The success and timing of regulatory submissions for the Phase 3 safety trial of GTX-104 are uncertain.
• Regulatory requirements or developments could impact the outcome and timing of the NDA application for GTX-104.
• Changes to clinical trial designs and regulatory pathways could affect the company's plans.
• Legislative, regulatory, political, and economic developments could impact the company's operations.
• Actual costs associated with Acasti's clinical trials may differ from management's current expectations.

Future Outlook

The company anticipates submitting an NDA for GTX-104 in the first half of 2025 and expects its cash runway to extend into the second calendar quarter of 2026.

Management Comments

• Prashant Kohli, CEO of Acasti, stated that the company continued to execute its focused strategy around GTX-104 and its pivotal Phase 3 STRIVE-ON safety trial.
• The CEO also noted that the company's balance sheet was enhanced by a $7.5 million private placement and prudent use of resources.

Industry Context

Acasti is focused on developing treatments for rare diseases, specifically aneurysmal subarachnoid hemorrhage (aSAH), which is a significant unmet medical need. The company's GTX-104 is a novel formulation of nimodipine that aims to improve treatment outcomes for aSAH patients.

Comparison to Industry Standards

• Acasti's focus on a rare disease with a high unmet need is consistent with the trend of pharmaceutical companies targeting niche markets with orphan drug designations.
• The company's cash runway extending into 2026 is a positive sign, as many biotech companies face funding challenges.
• The estimated $300 million addressable market in the US for GTX-104 is a significant opportunity, but the company will need to successfully navigate the regulatory approval process and commercialization.
• Other companies developing treatments for aSAH include pharmaceutical giants such as Bayer, which markets nimodipine, the active ingredient in GTX-104. Acasti's novel delivery method could provide a competitive advantage.
• The company's focus on intravenous delivery of nimodipine is a potential improvement over oral administration, which can be challenging in unconscious or dysphagic patients. This is a key differentiator compared to standard treatments.

Stakeholder Impact

• Shareholders may view the extended cash runway and progress in clinical trials positively.
• Employees may be reassured by the company's financial stability and progress.
• Patients with aSAH may benefit from the potential approval of GTX-104.
• Creditors may have increased confidence in the company's ability to meet its obligations.

Next Steps

• Continue patient enrollment in the STRIVE-ON Phase 3 trial.
• Prepare for the potential NDA submission with the FDA in the first half of 2025.
• Monitor and manage cash resources to ensure operations are funded into the second quarter of 2026.

Key Dates

Keywords

GTX-104, aSAH, STRIVE-ON trial, Nimodipine, Clinical Trial, NDA, Pharmaceutical, Biopharma, Orphan Drug, Subarachnoid Hemorrhage